Sawada M, Oe K, Hirata M, et al. - In this retrospective study, experts assessed 82 persons between June 2009 and December 2017 in order to contrast the efficiency of linezolid (LZD) (group L, n = 39) and daptomycin (DAP) (group D, n = 43) for treatment of periprosthetic joint infections (PJIs) harboring gram-positive microorganisms. From 72% of group L and 70% of group D persons, gram-positive pathogens were isolated. In groups, L and D, whole infection control rates against gram-positive pathogens were 79% and 77%, respectively. Moreover, without and with implant removal, in group L and group D, infection control rates were 94% and 58% and 75% and 80%, respectively. In group D, significantly greater clinical success rates and lower adverse event rates were noted, including higher RBC and platelet counts and lower CRP levels. However, in terms of infection control rates for refractory PJIs with gram-positive pathogens, the efficiency of LZD and DAP was comparable, DAP therapy notably reduced CRP levels and provoked fewer adverse events vs LZD treatment.